This is a phase 3 RCT to verify whether targeting a serum albumin level of 35 g/L or greater in patients admitted with acutely decompensated cirrhosis using repeated intravenous infusions of 20% HAS will reduce the incidence of infection, renal dysfunction, and mortality for the treatment period (maximum 14 days, or discharge if <14 days) compared with standard medical care. Here, ALB is linked to infection.